AUPH Aurinia Pharmaceuticals Inc.

On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]

Activists also report to the SEC on Allot Communications, Genco Shipping & Trading, Aurinia Pharmaceuticals, and Turtle Beach.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]

Aurinia Pharmaceuticals Inc. recently reported second-quarter 2026 results showing higher revenue and earnings year over year, reiterated its 2026 revenue and net product sales guidance, completed a large share buyback program, and finalized a settlement with Teva Pharmaceuticals that delays U.S. generic voclosporin entry until at least December 7, 2036. The Teva settlement meaningfully strengthens Aurinia’s intellectual property protection around voclosporin, potentially extending its U.S...

Aurinia Pharmaceuticals stock has delivered a 74.2% return over the past three years, and the broader valuation checks currently lean toward the shares being on the cheap side rather than fully priced. With fresh progress in its lupus nephritis franchise and pipeline, investors now face the question of whether that past gain already reflects the improving outlook or if the current price still leaves room based on fundamentals. Aurinia Pharmaceuticals has returned 74.2% over the last three...

Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.

Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.